About Zinc finger protein 215
Zinc finger protein 215 (ZNF215) is a protein
from Homo sapiens identified by UniProt accession
Q9UL58, 517 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Zinc finger protein 215 |
| UniProt accession | Q9UL58 |
| Gene | ZNF215 |
| Organism | Homo sapiens |
| Length | 517 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (17)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.02
- blood protein measurement · score 0.02
- cancer · score 0.02
- Beckwith-Wiedemann syndrome · score 0.01
- periodontitis · score 0.01
- neoplasm · score 0.01
- triple-negative breast cancer · score 0.01
- genetic disorder · score 0.01
- chronic obstructive pulmonary disease · score 0.00
- cryptorchidism · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UL58-F1 | alphafold | PREDICTED | 49.30 | — |
Amino-acid sequence (517 residues)
MQPLSKLMAI SKPRNLSLRE QREVLRADMS WQQETNPVVE THDSEASRQK FRHFQYLKVS GPHEALSQLW ELCLQWLRPE IHTKKQIIEL LVLEQFLAIL PEEVRTWVNL QHPNNSKDMV TLIEDVIEML EDEDMPCKDS ALQMGSIKEK MKAGSRTGKP QEPVTFKDVV VEFSKEEWGQ LDSAVKNLYR NVMLENFRNL NSLRKAHLLS KPFESLKLES KKKRWIMEKE IPRKTIFDMK SISGEESSHG VIMTRLTESG HPSSDAWKGE NWLYRNQKKW DINLPQEAFI PETIYTEEED FECSENKKSF DINSVSSICA IQVGIPSRKG SPKCDKFKTY FKFNLDSVGK QHSEYEYGND LSLSTDIRHQ KSHTTMNSYE CYQCGKAFCR SSSLIRHQII HTGEKPYKCS ECGRFFNRRT NLTKHQKLHA EAKACTSNKC GKAFSKSEDS NNPTLHFGNN FYQCVNCGKS FNRSSSLIRH QMIHTGEKPF KCKECSKAFN RSSNLVKHQK LHTRDKS
Explore Zinc finger protein 215 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets